Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications
Survivin (BIRC5) is a tumor-associated antigen (TAA) overexpressed in various tumors but present at low to undetectable levels in normal tissue. Survivin is known to have a high expression in breast cancer (e.g., Ductal Carcinoma in situ (DCIS) and triple negative breast cancer). Previous studies ha...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/14/11827 |
| _version_ | 1797198551571234816 |
|---|---|
| author | Sharon Wright Scott R. Burkholz Cathy Zelinsky Connor Wittman Richard T. Carback Paul E. Harris Tikoes Blankenberg Charles V. Herst Reid M. Rubsamen |
| author_facet | Sharon Wright Scott R. Burkholz Cathy Zelinsky Connor Wittman Richard T. Carback Paul E. Harris Tikoes Blankenberg Charles V. Herst Reid M. Rubsamen |
| author_sort | Sharon Wright |
| collection | DOAJ |
| description | Survivin (BIRC5) is a tumor-associated antigen (TAA) overexpressed in various tumors but present at low to undetectable levels in normal tissue. Survivin is known to have a high expression in breast cancer (e.g., Ductal Carcinoma in situ (DCIS) and triple negative breast cancer). Previous studies have not compared survivin expression levels in DCIS tumor samples to levels in adjacent, normal breast tissue from the same patient. To ensure the effective use of survivin as a target for T cell immunotherapy of breast cancer, it is essential to ascertain the varying levels of survivin expression between DCIS tumor tissue samples and the adjacent normal breast tissue taken from the same patient simultaneously. Next-generation sequencing of RNA (RNA-seq) in normal breast tissue and tumor breast tissue from five women presenting with DCIS for lumpectomy was used to identify sequence variation and expression levels of survivin. The identity of both tumor and adjacent normal tissue samples were corroborated by histopathology. Survivin was overexpressed in human breast tissue tumor samples relative to the corresponding adjacent human normal breast tissue. Wild-type survivin transcripts were the predominant species identified in all tumor tissue sequenced. This study demonstrates upregulated expression of wild type survivin in DCIS tumor tissue versus normal breast tissue taken from the same patient at the same time, and provides evidence that developing selective cytotoxic T lymphocyte (CTL) immunotherapy for DCIS targeting survivin warrants further study. |
| first_indexed | 2024-03-11T00:59:21Z |
| format | Article |
| id | doaj.art-1179a0d5618c4b0ab89f5e82db0ac5dd |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-04-24T07:01:40Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-1179a0d5618c4b0ab89f5e82db0ac5dd2024-04-22T07:29:54ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-07-0124141182710.3390/ijms241411827Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology ApplicationsSharon Wright0Scott R. Burkholz1Cathy Zelinsky2Connor Wittman3Richard T. Carback4Paul E. Harris5Tikoes Blankenberg6Charles V. Herst7Reid M. Rubsamen8Saint Mary’s Regional Medical Center, Reno, NV 89503, USAFlow Pharma Inc., Warrensville Heights, OH 44128, USASaint Mary’s Regional Medical Center, Reno, NV 89503, USASaint Mary’s Regional Medical Center, Reno, NV 89503, USAFlow Pharma Inc., Warrensville Heights, OH 44128, USAFlow Pharma Inc., Warrensville Heights, OH 44128, USAFlow Pharma Inc., Warrensville Heights, OH 44128, USAFlow Pharma Inc., Warrensville Heights, OH 44128, USASaint Mary’s Regional Medical Center, Reno, NV 89503, USASurvivin (BIRC5) is a tumor-associated antigen (TAA) overexpressed in various tumors but present at low to undetectable levels in normal tissue. Survivin is known to have a high expression in breast cancer (e.g., Ductal Carcinoma in situ (DCIS) and triple negative breast cancer). Previous studies have not compared survivin expression levels in DCIS tumor samples to levels in adjacent, normal breast tissue from the same patient. To ensure the effective use of survivin as a target for T cell immunotherapy of breast cancer, it is essential to ascertain the varying levels of survivin expression between DCIS tumor tissue samples and the adjacent normal breast tissue taken from the same patient simultaneously. Next-generation sequencing of RNA (RNA-seq) in normal breast tissue and tumor breast tissue from five women presenting with DCIS for lumpectomy was used to identify sequence variation and expression levels of survivin. The identity of both tumor and adjacent normal tissue samples were corroborated by histopathology. Survivin was overexpressed in human breast tissue tumor samples relative to the corresponding adjacent human normal breast tissue. Wild-type survivin transcripts were the predominant species identified in all tumor tissue sequenced. This study demonstrates upregulated expression of wild type survivin in DCIS tumor tissue versus normal breast tissue taken from the same patient at the same time, and provides evidence that developing selective cytotoxic T lymphocyte (CTL) immunotherapy for DCIS targeting survivin warrants further study.https://www.mdpi.com/1422-0067/24/14/11827breast cancerimmuno-oncologybioinformaticsartificial intelligencenext-generation sequencingsurvivin |
| spellingShingle | Sharon Wright Scott R. Burkholz Cathy Zelinsky Connor Wittman Richard T. Carback Paul E. Harris Tikoes Blankenberg Charles V. Herst Reid M. Rubsamen Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications International Journal of Molecular Sciences breast cancer immuno-oncology bioinformatics artificial intelligence next-generation sequencing survivin |
| title | Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications |
| title_full | Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications |
| title_fullStr | Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications |
| title_full_unstemmed | Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications |
| title_short | Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications |
| title_sort | survivin expression in luminal breast cancer and adjacent normal tissue for immuno oncology applications |
| topic | breast cancer immuno-oncology bioinformatics artificial intelligence next-generation sequencing survivin |
| url | https://www.mdpi.com/1422-0067/24/14/11827 |
| work_keys_str_mv | AT sharonwright survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT scottrburkholz survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT cathyzelinsky survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT connorwittman survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT richardtcarback survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT pauleharris survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT tikoesblankenberg survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT charlesvherst survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications AT reidmrubsamen survivinexpressioninluminalbreastcancerandadjacentnormaltissueforimmunooncologyapplications |